MDA-MB-361 Xenograft Model Service for Breast Cancer

The MDA-MB-361 xenograft model offers a specialized in vivo translational platform specifically optimized for evaluating candidate therapies targeting HER2-amplified, hormone-receptor-positive breast cancers. Alfa Cytology provides a comprehensive, end-to-end MDA-MB-361 xenograft model service, integrating fully authenticated cellular assets with standardized procedural and endocrine-supported protocols to accelerate preclinical oncology drug discovery timelines.

Overview of MDA-MB-361 Xenograft Model for Breast Cancer

The MDA-MB-361 cell line is a highly valuable human mammary carcinoma model in preclinical oncology, characterized as a distinct representation of the Luminal B molecular subtype of breast cancer. Originally isolated from the brain metastasis of a patient with advanced breast adenocarcinoma, this model uniquely exhibits both HER2 gene amplification (HER2+) and strong expression of ER. This co-expression profile establishes an intricate biological cross-talk between the growth factor receptor and steroid hormone signaling axes, making the MDA-MB-361 model an indispensable preclinical test matrix for studying mechanisms of therapeutic resistance and for validating novel HER2-targeted agents, SERDs, CDK4/6 inhibitors, and complex combination regimens bypassing endocrine escape pathways.

When established in vivo as a xenograft in immunocompromised mice, MDA-MB-361 cells form solid tumors that faithfully preserve the specific histological architecture and dual-biomarker expression signatures seen in clinical metastatic breast cancer patients.

Fig 1. Metformin induced cell survival inhibition in a dose-dependent manner across all glucose concentrations in MDA-MB-361 cells. (Sekar AP, et al., 2024)

Cell Line Information: MDA-MB-361

The MDA-MB-361 cell line maintains a stable epithelial-like morphology in vitro and reliably preserves its distinct HER2 amplification, ER expression, and metastatic-derived characteristics upon in vivo transplantation.

Our Services

Alfa Cytology provides a fully integrated, turnkey solution for the MDA-MB-361 Xenograft Model Service. Our dedication to quality begins with rigorous cell line authentication and mycoplasma testing. We manage every critical step of the preclinical journey—from standardized cell preparation, estradiol supplementation, orthotopic or subcutaneous inoculation, in-life monitoring, to comprehensive endpoint analyses including IHC for HER2 and ER status and PK/PD profiling. Leveraging our expertise in HER2+/ER+ luminal B breast cancer models, we deliver robust data packages tailored to accelerate your drug discovery programs.

Workflow of MDA-MB-361 Xenograft Model Construction

Alfa Cytology executes a standardized and strictly regulated workflow to build and validate the MDA-MB-361 xenograft model:

• Cell Culture & Quality Control: MDA-MB-361 cells are cultivated in cell-bank-certified growth media under optimized ambient parameters. Quality control verification involves mandatory STR profiling and mycoplasma clearance checks to guarantee phenotypic identity and purity before inoculation.
• Host Adaptation & Estrogen Priming: Standardized immunocompromised mice are selected based on study design and pre-implanted with controlled-release estradiol pellets to support the hormone-dependent growth components of the model. Animals are acclimated to controlled facility parameters to ensure baseline physiological stability.
• Precision Inoculation: A calibrated suspension of high-viability MDA-MB-361 cells is prepared and blended with a verified biological matrix carrier to overcome slow growth barriers and enhance cell survival. The mixture is precisely injected in vivo via subcutaneous or orthotopic routes.
• Longitudinal Growth Tracking: Following model establishment, tumor growth is tracked systematically using high-precision digital calipers under continuous health monitoring. Animal weights and general behavior are routinely recorded to establish dependable growth kinetics.
• Stratification & Dosing: Once the tumors reach a predetermined, statistically optimal volume range, animals are randomized into therapeutic cohorts to balance group parameters perfectly before dosing protocols begin.

Fig 2. MDA-MB-361 Xenograft Model Construction Workflow

Case Study - MDA-MB-361 Xenograft Model Development

In a recent preclinical trial conducted at Alfa Cytology, the MDA-MB-361 xenograft model was successfully utilized to evaluate the efficacy of a next-generation antibody-drug conjugate (ADC) combined with an endocrine therapeutic agent targeting dual HER2+ and ER+ breast cancer. Under optimized conditions featuring calibrated estradiol supplementation, our technical team achieved highly reproducible tumor engraftment and exceptionally uniform growth curves across all experimental arms, allowing for an unobstructed and definitive assessment of therapeutic efficacy.

Our Advantages

Choosing the right partner for your dual HER2-positive and hormone-receptor-positive breast cancer research is critical for generating high-quality, reproducible data. Alfa Cytology stands out by offering specialized expertise and high-standard preclinical services:

• Model Authenticity: Fully verified human tumor cell lines with stable, traceable genetic hallmarks.
• Technical Consistency: Optimized inoculation and hormone-supplementation protocols, ensuring uniform tumor growth and minimized variance.
• Multi-Parametric Endpoints: Capacity for advanced readouts, including digital tumor kinetics, target receptor expression analysis, and PK/PD tissue processing.
• Regulatory Compliance: Studies executed by a specialized team adhering strictly to international preclinical research standards.

Contact Us

Are you looking to advance your therapeutic pipeline against dual HER2-positive and hormone-receptor-positive breast cancer using the robust MDA-MB-361 xenograft platform? The expert scientific team at Alfa Cytology is ready to build a customized study design that fulfills your strategic research goals. Please contact us today to speak directly with an oncology specialist and request a project-specific consultation and quotation.

For research use only. Not intended for any clinical use.